Abstract
The aim of all medical treatment is "primum nihil nocere" ("First, do no harm"). Restoring the integrity of intestinal microbiota and optimising the immune response in recurrent infections, especially in the urinary tract, are treatment alternatives which are closer to this target than the usual focus on antibiotic prevention of recurrence. In the future, antibiotics will continue to be recommended for the prevention of urinary tract infections on a case-by-case basis. However, the problems of an excessive use of antibiotics, e.g. resistance and long-term interference with intestinal microbiota, are forcing us to search for alternatives. The use of probiotics alone or in combination with immunotherapeutics, or the sole use of immunotherapeutics, are important treatment options, which are already routinely available in clinical practice. These therapies are focused on the pathomechanism of an infection and tackle the root cause of the problem. Phytotherapeutics or small molecules like mannose, which restricts the adherence of bacteria to the urothelium, are complementary approaches. The EAU guidelines recommend the following treatments for the long-term prevention of urinary tract infections: Oral and parenteral immunostimulants (StroVac), local estrogen replacement and administration of Lactobacillus rhamnosus and Lactobacillus reuteri.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0001-7868 |
Sprache: | Deutsch |
Dokumenten ID: | 44494 |
Datum der Veröffentlichung auf Open Access LMU: | 27. Apr. 2018, 08:06 |
Letzte Änderungen: | 04. Nov. 2020, 13:20 |